X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Wockhardt with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT LTD. vs NATCO PHARMA - Comparison Results

WOCKHARDT LTD.    Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT LTD. NATCO PHARMA WOCKHARDT LTD./
NATCO PHARMA
 
P/E (TTM) x -19.2 13.7 - View Chart
P/BV x 2.0 3.9 52.2% View Chart
Dividend Yield % 0.0 1.1 0.2%  

Financials

 WOCKHARDT LTD.   NATCO PHARMA
EQUITY SHARE DATA
    WOCKHARDT LTD.
Mar-18
NATCO PHARMA
Mar-18
WOCKHARDT LTD./
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,0121,080 93.7%   
Low Rs532671 79.2%   
Sales per share (Unadj.) Rs355.9592.1 60.1%  
Earnings per share (Unadj.) Rs-60.3188.4 -32.0%  
Cash flow per share (Unadj.) Rs-46.8206.3 -22.7%  
Dividends per share (Unadj.) Rs0.018.25 0.1%  
Dividend yield (eoy) %00.9 0.1%  
Book value per share (Unadj.) Rs257.8833.6 30.9%  
Shares outstanding (eoy) m110.6336.90 299.8%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x2.21.5 146.6%   
Avg P/E ratio x-12.84.6 -275.5%  
P/CF ratio (eoy) x-16.54.2 -388.9%  
Price / Book Value ratio x3.01.1 285.0%  
Dividend payout %04.4 -0.4%   
Avg Mkt Cap Rs m85,37932,311 264.2%   
No. of employees `0006.34.8 129.5%   
Total wages/salary Rs m9,3713,256 287.8%   
Avg. sales/employee Rs Th6,295.04,522.5 139.2%   
Avg. wages/employee Rs Th1,498.3674.0 222.3%   
Avg. net profit/employee Rs Th-1,066.31,439.0 -74.1%   
INCOME DATA
Net Sales Rs m39,36921,848 180.2%  
Other income Rs m1,202404 297.6%   
Total revenues Rs m40,57122,252 182.3%   
Gross profit Rs m189,284 0.2%  
Depreciation Rs m1,495662 225.9%   
Interest Rs m2,555154 1,659.0%   
Profit before tax Rs m-2,8308,872 -31.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,5820-   
Tax Rs m2571,920 13.4%   
Profit after tax Rs m-6,6696,952 -95.9%  
Gross profit margin %042.5 0.1%  
Effective tax rate %-9.121.6 -42.0%   
Net profit margin %-16.931.8 -53.2%  
BALANCE SHEET DATA
Current assets Rs m33,79621,307 158.6%   
Current liabilities Rs m26,9175,920 454.7%   
Net working cap to sales %17.570.4 24.8%  
Current ratio x1.33.6 34.9%  
Inventory Days Days7973 108.3%  
Debtors Days Days89107 83.8%  
Net fixed assets Rs m39,66414,986 264.7%   
Share capital Rs m553369 149.9%   
"Free" reserves Rs m27,96830,353 92.1%   
Net worth Rs m28,52230,760 92.7%   
Long term debt Rs m21,7310-   
Total assets Rs m81,62037,151 219.7%  
Interest coverage x-0.158.6 -0.2%   
Debt to equity ratio x0.80-  
Sales to assets ratio x0.50.6 82.0%   
Return on assets %-5.019.1 -26.3%  
Return on equity %-23.422.6 -103.5%  
Return on capital %-7.729.3 -26.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m9,80710,322 95.0%   
Fx outflow Rs m1,7892,978 60.1%   
Net fx Rs m8,0197,343 109.2%   
CASH FLOW
From Operations Rs m6844,636 14.8%  
From Investments Rs m6,302-11,155 -56.5%  
From Financial Activity Rs m-7,6956,509 -118.2%  
Net Cashflow Rs m-664-18 3,688.9%  

Share Holding

Indian Promoters % 74.5 52.0 143.2%  
Foreign collaborators % 0.0 1.5 -  
Indian inst/Mut Fund % 2.3 7.8 29.3%  
FIIs % 7.7 16.6 46.3%  
ADR/GDR % 0.1 0.0 -  
Free float % 15.4 26.0 59.2%  
Shareholders   67,757 25,395 266.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT LTD. With:   ORCHID PHARMA LTD  CIPLA  TORRENT PHARMA  SUVEN LIFE  WYETH LTD  

Compare WOCKHARDT LTD. With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Finish Flat; IT and Pharma Stocks Witness Selling(Closing)

Share markets in India ended their trading session on a flattish note. Sectoral indices ended on a mixed note with stocks in the IT sector and pharma sector witnessing most of the selling pressure.

Related Views on News

WOCKHARDT LTD. Announces Quarterly Results (2QFY19); Net Profit Down 158.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, WOCKHARDT LTD. has posted a net profit of Rs 228 m (down 158.2% YoY). Sales on the other hand came in at Rs 11 bn (up 10.1% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

NATCO PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 115.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 115.2% YoY). Sales on the other hand came in at Rs 5 bn (up 27.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT LTD. SHARE PRICE


Nov 14, 2018 (Close)

TRACK WOCKHARDT LTD.

  • Track your investment in WOCKHARDT LTD. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON WOCKHARDT LTD.

WOCKHARDT LTD. - NATCO PHARMA COMPARISON

COMPARE WOCKHARDT LTD. WITH

MARKET STATS